Involvement of PPAR nuclear receptors in tissue injury and wound repair

Journal of Clinical Investigation

Volumn 116, Issue 3, 2006, Pages 598-606

  Michalik, Liliane ^a   Wahli, Walter ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BLEOMYCIN; CELL NUCLEUS RECEPTOR; CIGLITAZONE; CISPLATIN; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPENTENONE PROSTAGLANDIN; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GLUCOCORTICOID; ICOSANOID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA ANTAGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ANTAGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; POLYPHENOL DERIVATIVE; PROSTAGLANDIN DERIVATIVE; RESVERATROL; ROSIGLITAZONE; TRANSCRIPTION FACTOR; TROGLITAZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; WY 14463;

BRAIN ISCHEMIA; CANCER; CARCINOGENESIS; CELL DEATH; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; DEGENERATIVE DISEASE; DIABETIC NEPHROPATHY; FIBROSING ALVEOLITIS; GENE EXPRESSION; HUMAN; HYPERTRIGLYCERIDEMIA; IMMUNOCOMPETENT CELL; INFLAMMATION; INSULIN RESISTANCE; ISCHEMIA; KIDNEY INJURY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER INJURY; LUNG FIBROSIS; MYOFIBROBLAST; NEPHROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REPERFUSION; REVIEW; SEPSIS; SHOCK; SKIN INJURY; STOMACH INJURY; TISSUE INJURY; TISSUE NECROSIS; TISSUE REPAIR; WOUND; WOUND HEALING;

ANIMALS; HUMANS; ISCHEMIA; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; WOUND HEALING;

EID: 33644652740     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI27958     Document Type: Review

References (125)

1. Michalik, L., et al. 2001. Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR)alpha and PPARbeta mutant mice. J. Cell Biol. 154:799-814.
2. Barak, Y., et al. 2002. Effects of peroxisome proliferator-activated receptor delta on placentation, adiposity, and colorectal cancer. Proc. Natl. Acad. Sci. U. S. A. 99:303-308.
3. Mao-Qiang, M., et al. 2004. Peroxisome-proliferator-activated receptor (PPAR)-gamma activation stimulates keratinocyte differentiation. J. Invest. Dermatol. 123:305-312.
4. Lemberger, T., et al. 1994. Regulation of the peroxisome proliferator-activated receptor alpha gene by glucocorticoids. J. Biol. Chem. 269:24527-24530.
5. Tan, N.S., Michalik, L., Di-Poi, N., Desvergne, B., and Wahli, W. 2004. Critical roles of the nuclear receptor PPARbeta (peroxisome-proliferator- activated receptor beta) in skin wound healing. Biochem. Soc. Trans. 32:97-102.
6. Tan, N.S., et al. 2001. Critical roles of PPAR beta/delta in keratinocyte response to inflammation. Genes Dev. 15:3263-3277.
7. Di-Poi, N., Tan, N.S., Michalik, L., Wahli, W., and Desvergne, B. 2002. Antiapoptotic role of PPARbeta in keratinocytes via transcriptional control of the Akt1 signaling pathway. Mol. Cell. 10:721-733.
8. Tan, N.S., et al. 2004. Essential role of Smad3 in the inhibition of inflammation-induced PPARbeta/delta expression. EMBO J. 23:4211-4221.
9. Di-Poi, N., Desvergne, B., Michalik, L., and Wahli, W. 2005. Transcriptional repression of peroxisome proliferator-activated receptor beta/delta in murine keratinocytes by CCAAT/enhancer-binding proteins. J. Biol. Chem. 280:38700-38710.
10. Molitoris, B.A., and Sutton, T.A. 2004. Endothelial injury and dysfunction: role in the extension phase of acute renal failure. Kidney Int. 66:496-499.
11. Portilla, D., et al. 2000. Etomoxir-induced PPARalpha-modulated enzymes protect during acute renal failure. Am. J. Physiol. Renal Physiol. 278:F667-F675.
12. Arany, I., and Safirstein, R.L. 2003. Cisplatin nephrotoxicity. Semin. Nephrol. 23:460-464.
13. Li, S., Gokden, N., Okusa, M.D., Bhatt, R., and Portilla, D. 2005. Anti-inflammatory effect of fibrate protects from cisplatin-induced ARF. Am. J. Physiol. Renal Physiol. 289:F469-F480.
14. Li, S., et al. 2004. PPAR-alpha ligand ameliorates acute renal failure by reducing cisplatin-induced increased expression of renal endonuclease G. Am. J. Physiol. Renal Physiol. 287:F990-F998.
15. Letavernier, E., et al. 2005. Peroxisome proliferator-activated receptor beta/delta exerts a strong protection from ischemic acute renal failure. J. Am. Soc. Nephrol. 16:2395-2402.
16. Chung, B.H., et al. 2005. Protective effect of peroxisome proliferator activated receptor gamma agonists on diabetic and non-diabetic renal diseases. Nephrology (Carlton). 10(Suppl. 2):S40-S43.
17. Cuzzocrea, S. 2004. Peroxisome proliferator-activated receptors gamma ligands and ischemia and reperfusion injury. Vascul. Pharmacol. 41:187-195.
18. Guan, Y. 2004. Peroxisome proliferator-activated receptor family and its relationship to renal complications of the metabolic syndrome. J. Am. Soc. Nephrol. 15:2801-2815.
19. Panchapakesan, U., Sumual, S., Pollock, C.A., and Chen, X. 2005. PPARgamma agonists exert antifibrotic effects in renal tubular cells exposed to high glucose. Am. J. Physiol. Renal Physiol. 289:F1153-F1158.
20. Zafiriou, S., Stanners, S.R., Polhill, T.S., Poronnik, P., and Pollock, C.A. 2004. Pioglitazone increases renal tubular cell albumin uptake but limits proinflammatory and fibrotic responses. Kidney Int. 65:1647-1653.
21. Sivarajah, A., et al. 2003. Agonists of peroxisome-proliferator activated receptor-gamma reduce renal ischemia/reperfusion injury. Am. J. Nephrol. 23:267-276.
22. Zheng, F., et al. 2002. Upregulation of type I collagen by TGF-beta in mesangial cells is blocked by PPARgamma activation. Am. J. Physiol. Renal Physiol. 282:F639-F648.
23. Chatterjee, P.K., et al. 2004. The cyclopentenone prostaglandin 15-deoxy-delta(12,14)-prostaglandin J2 ameliorates ischemic acute renal failure. Cardiovasc. Res. 61:630-643.
24. King, R.C., et al. 2000. Reperfusion injury significantly impacts clinical outcome after pulmonary transplantation. Ann. Thorac. Surg. 69:1681-1685.
25. Ito, K., et al. 2004. Protective effects of preischemic treatment with pioglitazone, a peroxisome proliferator-activated receptor-gamma ligand, on lung ischemia-reperfusion injury in rats. Eur. J. Cardiothorac. Surg. 25:530-536.
26. Okada, M., Yan, S.F., and Pinsky, D.J. 2002. Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) activation suppresses ischemic induction of Egr-1 and its inflammatory gene targets. FASEB J. 16:1861-1868.
27. Gross, T.J., and Hunninghake, G.W. 2001. Idiopathic pulmonary fibrosis. N. Engl. J. Med. 345:517-525.
28. Sleijfer, S. 2001. Bleomycin-induced pneumonitis. Chest. 120:617-624.
29. Burgess, H.A., et al. 2005. PPARgamma agonists inhibit TGF-beta induced pulmonary myofibroblast differentiation and collagen production: implications for therapy of lung fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 288:L1146-L1153.
30. Genovese, T., et al. 2005. Effect of rosiglitazone and 15-deoxy-delta12,14-prostaglandin J2 on bleomycin-induced lung injury. Eur. Respir. J. 25:225-234.
31. Cappell, M.S. 1998. Intestinal (mesenteric) vasculopathy. II. Ischemic colitis and chronic mesenteric ischemia [review]. Gastroenterol. Clin. North Am. 27:827-860, vi.
32. Nakajima, A., et al. 2001. Endogenous PPAR gamma mediates anti-inflammatory activity in murine ischemia-reperfusion injury. Gastroenterology. 120:460-469.
33. Naito, Y., et al. 2002. Suppression of intestinal ischemia-reperfusion injury by a specific peroxisome proliferator-activated receptor-gamma ligand, pioglitazone, in rats. Redox Rep. 7:294-299.
34. Cuzzocrea, S., et al. 2003. Rosiglitazone and 15-deoxy-delta12,14- prostaglandin J2, ligands of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), reduce ischaemia/reperfusion injury of the gut. Br. J. Pharmacol. 140:366-376.
35. Cuzzocrea, S., et al. 2004. WY 14643, a potent exogenous PPAR-alpha ligand, reduces intestinal injury associated with splanchnic artery occlusion shock. Shock. 22:340-346.
36. Sato, N., et al. 2005. Differential induction of PPAR gamma by luminal glutamine and iNOS by luminal arginine in the rodent post ischemic small bowel. Am. J. Physiol. Gastrointest. Liver Physiol. doi:10.1152/ajpgi.00248.2005.
37. Ichikawa, H., et al. 2002. A specific peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligand, pioglitazone, ameliorates gastric mucosal damage induced by ischemia and reperfusion in rats. Redox Rep. 7:343-346.
38. Konturek, P.C., et al. 2003. Pioglitazone, a specific ligand of the peroxisome proliferator-activated receptor gamma reduces gastric mucosal injury induced by ischaemia/reperfusion in rat. Scand. J. Gastroenterol. 38:468-476.
39. Wada, K., et al. 2004. Protective effect of endogenous PPARgamma against acute gastric mucosal lesions associated with ischemia-reperfusion. Am. J. Physiol. Gastrointest. Liver Physiol. 287:G452-G458.
40. Villegas, I., Martin, A.R., Toma, W., and de la Lastra, C.A. 2004. Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, protects against gastric ischemia-reperfusion damage in rats: role of oxygen free radicals generation. Eur. J. Pharmacol. 505:195-203.
41. Elsharkawy, A.M., Oakley, F., and Mann, D.A. 2005. The role and regulation of hepatic stellate cell apoptosis in reversal of liver fibrosis. Apoptosis. 10:927-939.
42. Iredale, J.P. 2003. Cirrhosis: new research provides a basis for rational and targeted treatments. BMJ. 327:143-147.
43. Xu, J., Fu, Y., and Chen, A. 2003. Activation of peroxisome proliferator-activated receptor-gamma contributes to the inhibitory effects of curcumin on rat hepatic stellate cell growth. Am. J. Physiol. Gastrointest. Liver Physiol. 285:G20-G30.
44. Miyahara, T., et al. 2000. Peroxisome proliferator-activated receptors and hepatic stellate cell activation. J. Biol. Chem. 275:35715-35722.
45. Marra, F., et al. 2000. Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells. Gastroenterology. 119:466-478.
46. Galli, A., et al. 2002. Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology. 122:1924-1940.
47. Hazra, S., et al. 2004. Peroxisome proliferator-activated receptor gamma induces a phenotypic switch from activated to quiescent hepatic stellate cells. J. Biol. Chem. 279:11392-11401.
48. Yavrom, S., et al. 2005. Peroxisome proliferator-activated receptor gamma suppresses proximal alpha 1(I) collagen promoter via inhibition of p300-facilitated NF-I binding to DNA in hepatic stellate cells. J. Biol. Chem. 280:40650-40659.
49. She, H., Xiong, S., Hazra, S., and Tsukamoto, H. 2005. Adipogenic transcriptional regulation of hepatic stellate cells. J. Biol. Chem. 280:4959-4967.
50. Planaguma, A., et al. 2005. The selective cyclooxygenase-2 inhibitor SC-236 reduces liver fibrosis by mechanisms involving non-parenchymal cell apoptosis and PPARgamma activation. FASEB J. 19:1120-1122.
51. Fiorucci, S., et al. 2005. Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis. J. Pharmacol. Exp. Ther. 315:58-68.
52. Marra, F., et al. 2005. Thiazolidinedione treatment inhibits bile duct proliferation and fibrosis in a rat model of chronic cholestasis. World J. Gastroenterol. 11:4931-4938.
53. Hellemans, K., et al. 2003. Peroxisome proliferator-activated receptor-beta signaling contributes to enhanced proliferation of hepatic stellate cells. Gastroenterology. 124:184-201.
54. Toyama, T., et al. 2004. PPARalpha ligands activate antioxidant enzymes and suppress hepatic fibrosis in rats. Biochem. Biophys. Res. Commun. 324:697-704.
55. Okaya, T., and Lentsch, A.B. 2004. Peroxisome proliferator-activated receptor-alpha regulates postischemic liver injury. Am. J. Physiol. Gastrointest. Liver Physiol. 286:G606-G612.
56. Rao, M.S., Peters, J.M., Gonzalez, F.J., and Reddy, J.K. 2002. Hepatic regeneration in peroxisome proliferator-activated receptor alpha-null mice after partial hepatectomy. Hepatol. Res. 22:52-57.
57. Wheeler, M.D., et al. 2003. Impaired Ras membrane association and activation in PPARalpha knockout mice after partial hepatectomy. Am. J. Physiol. Gastrointest. Liver Physiol. 284:G302-G312.
58. Anderson, S.P., et al. 2002. Delayed liver regeneration in peroxisome proliferator-activated receptor-alpha-null mice. Hepatology. 36:544-554.
59. Skrtic, S., et al. 2005. Decreased expression of peroxisome proliferator-activated receptor alpha and liver fatty acid binding protein after partial hepatectomy of rats and mice. Liver Int. 25:33-40.
60. Jonas, S. 1995. Prophylactic pharmacologic neuroprotection against focal cerebral ischemia. Ann. N. Y. Acad. Sci. 765:21-25; discussion 26-27.
61. Bloomfield Rubins, H., et al. 2001. Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT). Circulation. 103:2828-2833.
62. Deplanque, D., et al. 2003. Peroxisome proliferator-activated receptor-alpha activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment. J. Neurosci. 23:6264-6271.
63. Inoue, H., et al. 2003. Brain protection by resveratrol and fenofibrate against stroke requires peroxisome proliferator-activated receptor alpha in mice. Neurosci. Lett. 352:203-206.
64. Santos, M.J., et al. 2005. Peroxisomal proliferation protects from beta-amyloid neurodegeneration. J. Biol. Chem. 280:41057-41068.
65. Shimazu, T., et al. 2005. A peroxisome proliferator-activated receptor-gamma agonist reduces infarct size in transient but not in permanent ischemia. Stroke. 36:353-359.
66. Sundararajan, S., et al. 2005. Peroxisome proliferator-activated receptor-gamma ligands reduce inflammation and infarction size in transient focal ischemia. Neuroscience. 130:685-696.
67. Zhao, Y., Patzer, A., Gohlke, P., Herdegen, T., and Culman, J. 2005. The intracerebral application of the PPARgamma-ligand pioglitazone confers neuroprotection against focal ischaemia in the rat brain. Eur J. Neurosci. 22:278-282.
68. Kielian, T., and Drew, P.D. 2003. Effects of peroxisome proliferator-activated receptor-gamma agonists on central nervous system inflammation. J. Neurosci. Res. 71:315-325.
69. Schutz, B., et al. 2005. The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice. J. Neurosci. 25:7805-7812.
70. Barger, P.M., and Kelly, D.P. 2000. PPAR signaling in the control of cardiac energy metabolism. Trends Cardiovasc. Med. 10:238-245.
71. Fragasso, G., et al. 2003. Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy. Am. Heart J. 146:E18.
72. Sambandam, N., et al. 2006. Chronic activation of PPARalpha is detrimental to cardiac recovery following ischemia. Am. J. Physiol. Heart Circ. Physiol. 290:H87-H95.
73. Kantor, P.F., Lucien, A., Kozak, R., and Lopaschuk, G.D. 2000. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ. Res. 86:580-588.
74. Cook, S.A., Matsui, T., Li, L., and Rosenzweig, A. 2002. Transcriptional effects of chronic Akt activation in the heart. J. Biol. Chem. 277:22528-22533.
75. Yue, T.L., et al. 2003. Activation of peroxisome proliferator-activated receptor-alpha protects the heart from ischemia/reperfusion injury. Circulation. 108:2393-2399.
76. Wayman, N.S., et al. 2002. Ligands of the peroxisome proliferator- activated receptors (PPARgamma and PPAR-alpha) reduce myocardial infarct size. FASEB J. 16:1027-1040.
77. Tabernero, A., et al. 2002. Activation of the peroxisome proliferator-activated receptor alpha protects against myocardial ischaemic injury and improves endothelial vasodilatation. BMC Pharmacol. 2:10.
78. Lee, T.M., and Chou, T.F. 2003. Troglitazone administration limits infarct size by reduced phosphorylation of canine myocardial connexin43 proteins. Am. J. Physiol. Heart Circ. Physiol. 285:H1650-H1659.
79. Shiomi, T., et al. 2002. Pioglitazone, a peroxisome proliferator- activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation. 106:3126-3132.
80. Yue, T.-L., et al. 2001. In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Circulation. 104:2588-2594.
81. Khandoudi, N., et al. 2002. Rosiglitazone, a peroxisome proliferator-activated receptor-gamma, inhibits the Jun NH(2)-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury. Diabetes. 51:1507-1514.
82. Sidell, R.J., et al. 2002. Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the zucker fatty rat heart. Diabetes. 51:1110-1117.
83. Liu, H.R., et al. 2004. Anti-apoptotic effects of rosiglitazone in hypercholesterolemic rabbits subjected to myocardial ischemia and reperfusion. Cardiovasc. Res. 62:135-144.
84. Dormandy, J.A., et al. 2005. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 366:1279-1289.
85. Delea, T.E., Edelsberg, J.S., Hagiwara, M., Oster, G., and Phillips, L.S. 2003. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study. Diabetes Care. 26:2983-2989.
86. Lygate, C.A., et al. 2003. The PPARgamma-activator rosiglitazone does not alter remodeling but increases mortality in rats post-myocardial infarction. Cardiovasc. Res. 58:632-637.
87. Xu, Y., et al. 2003. Deleterious effects of acute treatment with a peroxisome proliferator-activated receptor-gamma activator in myocardial ischemia and reperfusion in pigs. Diabetes. 52:1187-1194.
88. Iglarz, M., et al. 2003. Peroxisome proliferator-activated receptor-alpha and receptor-gamma activators prevent cardiac fibrosis in mineralocorticoid- dependent hypertension. Hypertension. 42:737-743.
89. Ogata, T., et al. 2004. Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-kappa-B pathway. J. Am. Coll. Cardiol. 43:1481-1488.
90. Diep, Q.N., et al. 2004. PPAR alpha activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats. J. Mol. Cell. Cardiol. 36:295-304.
91. Chen, K., Li, D., Zhang, X., Hermonat, P.L., and Mehta, J.L. 2004. Anoxia-reoxygenation stimulates collagen type-I and MMP-1 expression in cardiac fibroblasts: modulation by the PPAR-gamma ligand pioglitazone. J. Cardiovasc. Pharmacol. 44:682-687.
92. Nikolaidis, L.A., and Levine, T.B. 2004. Peroxisome proliferator activator receptors (PPAR), insulin resistance, and cardiomyopathy: friends or foes for the diabetic patient with heart failure? Cardiol. Rev. 12:158-170.
93. Rizza, R., Henry, R., and Kahn, R. 2005. Commentary on the results and clinical implications of the PROactive study. Diabetes Care. 28:2965-2967.
94. Baue, A.E., Durham, R., and Faist, E. 1998. Systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), multiple organ failure (MOF): are we winning the battle? Shock. 10:79-89.
95. Abdelrahman, M., Sivarajah, A., and Thiemermann, C. 2005. Beneficial effects of PPAR-gamma ligands in ischemia-reperfusion injury, inflammation and shock. Cardiovasc. Res. 65:772-781.
96. Zingarelli, B., and Cook, J.A. 2005. Peroxisome proliferator-activated receptor-gamma is a new therapeutic target in sepsis and inflammation. Shock. 23:393-399.
97. Kaplan, J.M., et al. 2005. 15-Deoxy-Delta(12,14)-prostaglandin J(2) (15D-PGJ(2)), a peroxisome proliferator activated receptor gamma ligand, reduces tissue leukosequestration and mortality in endotoxic shock. Shock. 24:59-65.
98. Wiel, E., et al. 2005. Pretreatment with peroxysome proliferator- activated receptor alpha agonist fenofibrate protects endothelium in rabbit Escherichia coli endotoxin-induced shock. Intensive Care Med. 31:1269-1279.
99. Abdelrahman, M., Collin, M., and Thiemermann, C. 2004. The peroxisome proliferator-activated receptor-gamma ligand 15-deoxyDelta12,14 prostaglandin J2 reduces the organ injury in hemorrhagic shock. Shock. 22:555-561.
100. Marshall, J.C., et al. 2005. Preclinical models of shock and sepsis: what can they tell us? Shock. 24(Suppl. 1):1-6.
101. Chang, H.Y., et al. 2005. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc. Natl. Acad. Sci. U. S. A. 102:3738-3743.
102. Michalik, L., Desvergne, B., and Wahli, W. 2004. Peroxisome-proliferator- activated receptors and cancers: complex stories. Nat. Rev. Cancer. 4:61-70.
103. Margeli, A., Kouraklis, G., and Theocharis, S. 2003. Peroxisome proliferator activated receptor-gamma (PPAR-gamma) ligands and angiogenesis. Angiogenesis. 6:165-169.
104. Keshamouni, V.G., et al. 2005. PPAR-gamma activation inhibits angiogenesis by blocking ELR+CXC chemokine production in non-small cell lung cancer. Neoplasia. 7:294-301.
105. Sarayba, M.A., et al. 2005. Inhibition of corneal neovascularization by a peroxisome proliferator-activated receptor-gamma ligand. Exp. Eye Res. 80:435-442.
106. Panigrahy, D., et al. 2002. PPARγ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J. Clin. Invest. 110:923-932. doi:10.1172/JCI200215634.
107. Murata, T., et al. 2000. Peroxisome proliferator-activated receptor-gamma ligands inhibit choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 41:2309-2317.
108. Xin, X., Yang, S., Kowalski, J., and Gerritsen, M.E. 1999. Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo. J. Biol. Chem. 274:9116-9121.
109. Goetze, S., et al. 2002. Leptin induces endothelial cell migration through Akt, which is inhibited by PPARgamma-ligands. Hypertension. 40:748-754.
110. Rieusset, J., Auwerx, J., and Vidal, H. 1999. Regulation of gene expression by activation of the peroxisome proliferator-activated receptor gamma with rosiglitazone (BRL 49653) in human adipocytes. Biochem. Biophys. Res. Commun. 265:265-271.
111. Kersten, S., et al. 2000. Characterization of the fasting-induced adipose factor FIAF, a novel peroxisome proliferator-activated receptor target gene. J. Biol. Chem. 275:28488-28493.
112. Yoon, J.C., et al. 2000. Peroxisome proliferator-activated receptor gamma target gene encoding a novel angiopoietin-related protein associated with adipose differentiation. Mol. Cell. Biol. 20:5343-5349.
113. Belanger, A.J., et al. 2002. Hypoxia up-regulates expression of peroxisome proliferator-activated receptor gamma angiopoietin-related gene (PGAR) in cardiomyocytes: role of hypoxia inducible factor 1alpha. J. Mol. Cell. Cardiol. 34:765-774.
114. Varet, J., et al. 2003. Fenofibrate inhibits angiogenesis in vitro and in vivo. Cell. Mol. Life Sci. 60:810-819.
115. Kasai, T., Miyauchi, K., Yokoyama, T., Aihara, K., and Daida, H. 2005. Efficacy of peroxisome proliferative activated receptor (PPAR)-alpha ligands, fenofibrate, on intimal hyperplasia and constrictive remodeling after coronary angioplasty in porcine models. Atherosclerosis. doi:10.1016/j.atherosclerosis. 2005.10.047.
116. Nijsten, T., Geluyckens, E., Colpaert, C., and Lambert, J. 2005. Peroxisome proliferator-activated receptors in squamous cell carcinoma and its precursors. J. Cutan. Pathol. 32:340-347.
117. Jaeckel, E.C., et al. 2001. Correlation of expression of cyclooxygenase-2, vascular endothelial growth factor, and peroxisome proliferator-activated receptor delta with head and neck squamous cell carcinoma. Arch. Otolaryngol. Head Neck Surg. 127:1253-1259.
118. Shiojima, I., and Walsh, K. 2002. Role of Akt signaling in vascular homeostasis and angiogenesis. Circ. Res. 90:1243-1250.
119. Devchand, P.R., et al. 1996. The PPARalpha-leukotriene B4 pathway to inflammation control. Nature. 384:39-43.
120. Powell, D.W., Adegboyega, P.A., Di Mari, J.F., and Mifflin, R.C. 2005. Epithelial cells and their neighbors. I. Role of intestinal myofibroblasts in development, repair, and cancer. Am. J. Physiol. Gastrointest. Liver Physiol. 289:G2-G7.
121. Hetzel, M., Bachem, M., Anders, D., Trischler, G., and Faehling, M. 2005. Different effects of growth factors on proliferation and matrix production of normal and fibrotic human lung fibroblasts. Lung. 183:225-237.
122. Bataller, R., and Brenner, D.A. 2005. Liver fibrosis. J. Clin. Invest. 115:209-218. doi:10.1172/JCI200524282.
123. Chatziantoniou, C., and Dussaule, J.C. 2005. Insights into the mechanisms of renal fibrosis: is it possible to achieve regression? Am. J. Physiol. Renal Physiol. 289:F227-F234.
124. Pershadsingh, H.A. 2005. Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferator-activated receptor-γ. Int. J. Biochem. Cell Biol. doi:10.1016/j.biocel.2005.08.006.
125. Yang, Z.Z., et al. 2005. Dosage-dependent effects of Akt1/protein kinase Balpha (PKBalpha) and Akt3/PKBgamma on thymus, skin, and cardiovascular and nervous system development in mice. Mol. Cell. Biol. 25:10407-10418.